International Journal of Hematology

, Volume 93, Issue 2, pp 163–169 | Cite as

Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience

  • Moon Ju Jang
  • So Young Chong
  • In-Ho Kim
  • Jee-Hyun Kim
  • Chul-Won Jung
  • Ja Young Kim
  • Ji-Chan Park
  • Sun Min Lee
  • Yeo-Kyeoung Kim
  • Ji-Eun Lee
  • Sung-Su Jang
  • Jin-Seok Kim
  • Deog-Yeon Jo
  • Dae-Young Zang
  • Young-Yiul Lee
  • Ho-Young Yhim
  • Doyeun Oh
Original Article


The clinical significance of ADAMTS13 activity for response to treatment, mortality rate, recurrence, and prognosis is unclear. Therefore, we investigated the characteristics of severe ADAMTS13 deficiency and evaluated its prognostic features in Thrombotic thrombocytopenic purpura (TTP). The Korean TTP Registry includes 66 patients from 13 teaching hospitals in Korea who received the diagnosis of TTP from January 2005 to December 2008. Blood samples obtained upon admission were sent for ADAMTS13 analysis (multimer analysis by sodium dodecyl sulfate electrophoresis) to a central laboratory along with patient clinical information. Patients with severe ADAMTS13 deficiency had lower serum creatinine levels (P = 0.001) than patients with non-severe ADAMTS13 deficiency. Although severe ADAMTS13 deficiency was associated with better response rate (75 vs. 53%, P = 0.145), remission rate (81 vs. 61%, P = 0.209), and mortality rate (19 vs. 31%, P = 0.508) than non-severe ADAMTS13 deficiency, treatment outcomes did not differ significantly between groups. After adjusting for clinical and laboratory features, multivariate analysis did not reveal any independent risk factors for TTP-associated mortality. Patients with severe ADAMTS13 deficiency had lower serum creatinine levels at presentation, but severe ADAMTS13 activity deficiency at TTP diagnosis does not appear to have prognostic significance.


ADAMTS-13 Thrombotic thrombocytopenic purpura (TTP) Von Willebrand factor (VWF) cleaving protease Plasma exchange (PE) Microangiopathic hemolytic anemia 


  1. 1.
    Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600.CrossRefPubMedGoogle Scholar
  2. 2.
    Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78:1456–61.CrossRefPubMedGoogle Scholar
  3. 3.
    Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223–34.PubMedGoogle Scholar
  4. 4.
    Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–94.CrossRefPubMedGoogle Scholar
  5. 5.
    Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–63.CrossRefPubMedGoogle Scholar
  6. 6.
    Moake JL. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol. 2004;41:4–14.CrossRefPubMedGoogle Scholar
  7. 7.
    Tsai HM. Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura. Int J Hematol. 2002;76(Suppl 2):132–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Dong JF, Moake JL, Bernardo A, Fujikawa K, Ball C, Nolasco L, Lopez JA, Cruz MA. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem. 2003;278:29633–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98:1654–61.CrossRefPubMedGoogle Scholar
  11. 11.
    Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–94.CrossRefPubMedGoogle Scholar
  12. 12.
    Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Int Med. 2000;132:794–9.PubMedGoogle Scholar
  13. 13.
    Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Fremeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004;83:233–44.CrossRefGoogle Scholar
  14. 14.
    Mori Y, Wada H, Gabazza EC, Minami N, Nobori T, Shiku H, Yagi H, Ishizashi H, Matsumoto M, Fujimura Y. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion. 2002;42:572–80.CrossRefPubMedGoogle Scholar
  15. 15.
    Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001;98:1765–72.CrossRefPubMedGoogle Scholar
  16. 16.
    Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol. 2004;41:68–74.CrossRefPubMedGoogle Scholar
  18. 18.
    Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, Bevan D, Mackie I, Machin S. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142:819–26.CrossRefPubMedGoogle Scholar
  19. 19.
    Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578–84.CrossRefPubMedGoogle Scholar
  20. 20.
    Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2004;127:433–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Ito-Habe N, Wada H, Matsumoto M, Fujimura Y, Murata M, Izuno T, Sugita M, Ikeda Y. A second national questionnaire survey of TMA. Int J Hematol 2010;92:68–75. doi: 10.1007/s12185-010-0599-4.Google Scholar
  23. 23.
    George JN, Vesely SK, Terrell DR. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol. 2004;41:60–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, Poullin P, Malot S, Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP, Ridel C, Rondeau E, Pourrat J, Girault S, Bordessoule D, Saheb S, Ramakers M, Hamidou M, Vernant JP, Guidet B, Wolf M, Veyradier A. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 2010;5:e10208.Google Scholar
  25. 25.
    Lammle B, Kremer Hovinga JA, George JN. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica. 2008;93:172–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Reti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93:232–9.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2011

Authors and Affiliations

  • Moon Ju Jang
    • 1
  • So Young Chong
    • 1
  • In-Ho Kim
    • 2
  • Jee-Hyun Kim
    • 2
  • Chul-Won Jung
    • 3
  • Ja Young Kim
    • 4
  • Ji-Chan Park
    • 5
  • Sun Min Lee
    • 6
  • Yeo-Kyeoung Kim
    • 7
  • Ji-Eun Lee
    • 8
  • Sung-Su Jang
    • 9
  • Jin-Seok Kim
    • 10
  • Deog-Yeon Jo
    • 11
  • Dae-Young Zang
    • 12
  • Young-Yiul Lee
    • 13
  • Ho-Young Yhim
    • 14
  • Doyeun Oh
    • 1
  1. 1.Department of Internal Medicine, School of MedicineCHA UniversitySeongnamKorea
  2. 2.Department of Internal MedicineSeoul National University College of MedicineSeoulKorea
  3. 3.Department of Internal Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea
  4. 4.Department of Laboratory Medicine, College of MedicineCatholic University of KoreaSeoulKorea
  5. 5.Department of Internal Medicine, College of MedicineCatholic University of KoreaSeoulKorea
  6. 6.Department of Internal MedicineBusan National University College of MedicinePusanKorea
  7. 7.Department of Internal MedicineChonnam National University College of MedicineGwangjuKorea
  8. 8.Department of Internal MedicineKorea University College of MedicineSeoulKorea
  9. 9.Department of Laboratory MedicineUniversity of Ulsan College of MedicineSeoulKorea
  10. 10.Department of Internal MedicineYonsei University College of MedicineSeoulKorea
  11. 11.Department of Internal MedicineChungnam National University College of MedicineDaejeonKorea
  12. 12.Department of Internal MedicineHallym University Sacred Heart Hospital, Hallym University College of MedicineChuncheonKorea
  13. 13.Department of Internal MedicineHanyang University College of MedicineSeoulKorea
  14. 14.Department of Internal MedicineChonbuk National University Medical SchoolJeonjuKorea

Personalised recommendations